Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research
Prostate cancer (PCa) has been known as the most prevalent cancer disease and the second leading cause of cancer mortality in men almost all over the globe. There is an urgent need for establishment of PCa models that can recapitulate the progress of genomic landscapes and molecular alterations duri...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/25/2/1093 |
_version_ | 1797339826493587456 |
---|---|
author | Mohammad Waseem Bi-Dar Wang |
author_facet | Mohammad Waseem Bi-Dar Wang |
author_sort | Mohammad Waseem |
collection | DOAJ |
description | Prostate cancer (PCa) has been known as the most prevalent cancer disease and the second leading cause of cancer mortality in men almost all over the globe. There is an urgent need for establishment of PCa models that can recapitulate the progress of genomic landscapes and molecular alterations during development and progression of this disease. Notably, several organoid models have been developed for assessing the complex interaction between PCa and its surrounding microenvironment. In recent years, PCa organoids have been emerged as powerful in vitro 3D model systems that recapitulate the molecular features (such as genomic/epigenomic changes and tumor microenvironment) of PCa metastatic tumors. In addition, application of organoid technology in mechanistic studies (i.e., for understanding cellular/subcellular and molecular alterations) and translational medicine has been recognized as a promising approach for facilitating the development of potential biomarkers and novel therapeutic strategies. In this review, we summarize the application of PCa organoids in the high-throughput screening and establishment of relevant xenografts for developing novel therapeutics for metastatic, castration resistant, and neuroendocrine PCa. These organoid-based studies are expected to expand our knowledge from basic research to clinical applications for PCa diseases. Furthermore, we also highlight the optimization of PCa cultures and establishment of promising 3D organoid models for in vitro and in vivo investigations, ultimately facilitating mechanistic studies and development of novel clinical diagnosis/prognosis and therapies for PCa. |
first_indexed | 2024-03-08T09:53:04Z |
format | Article |
id | doaj.art-98b1ac722979436cb1fc5f9630b64717 |
institution | Directory Open Access Journal |
issn | 1661-6596 1422-0067 |
language | English |
last_indexed | 2024-03-08T09:53:04Z |
publishDate | 2024-01-01 |
publisher | MDPI AG |
record_format | Article |
series | International Journal of Molecular Sciences |
spelling | doaj.art-98b1ac722979436cb1fc5f9630b647172024-01-29T13:56:58ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672024-01-01252109310.3390/ijms25021093Organoids: An Emerging Precision Medicine Model for Prostate Cancer ResearchMohammad Waseem0Bi-Dar Wang1Department of Pharmaceutical Sciences, School of Pharmacy and Health Professions, University of Maryland Eastern Shore, Princess Anne, MD 21853, USADepartment of Pharmaceutical Sciences, School of Pharmacy and Health Professions, University of Maryland Eastern Shore, Princess Anne, MD 21853, USAProstate cancer (PCa) has been known as the most prevalent cancer disease and the second leading cause of cancer mortality in men almost all over the globe. There is an urgent need for establishment of PCa models that can recapitulate the progress of genomic landscapes and molecular alterations during development and progression of this disease. Notably, several organoid models have been developed for assessing the complex interaction between PCa and its surrounding microenvironment. In recent years, PCa organoids have been emerged as powerful in vitro 3D model systems that recapitulate the molecular features (such as genomic/epigenomic changes and tumor microenvironment) of PCa metastatic tumors. In addition, application of organoid technology in mechanistic studies (i.e., for understanding cellular/subcellular and molecular alterations) and translational medicine has been recognized as a promising approach for facilitating the development of potential biomarkers and novel therapeutic strategies. In this review, we summarize the application of PCa organoids in the high-throughput screening and establishment of relevant xenografts for developing novel therapeutics for metastatic, castration resistant, and neuroendocrine PCa. These organoid-based studies are expected to expand our knowledge from basic research to clinical applications for PCa diseases. Furthermore, we also highlight the optimization of PCa cultures and establishment of promising 3D organoid models for in vitro and in vivo investigations, ultimately facilitating mechanistic studies and development of novel clinical diagnosis/prognosis and therapies for PCa.https://www.mdpi.com/1422-0067/25/2/1093prostate cancerorganoids3D modelprecision medicinein vitro and in vivo modelscastration resistant prostate cancer (CRPC) |
spellingShingle | Mohammad Waseem Bi-Dar Wang Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research International Journal of Molecular Sciences prostate cancer organoids 3D model precision medicine in vitro and in vivo models castration resistant prostate cancer (CRPC) |
title | Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research |
title_full | Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research |
title_fullStr | Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research |
title_full_unstemmed | Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research |
title_short | Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research |
title_sort | organoids an emerging precision medicine model for prostate cancer research |
topic | prostate cancer organoids 3D model precision medicine in vitro and in vivo models castration resistant prostate cancer (CRPC) |
url | https://www.mdpi.com/1422-0067/25/2/1093 |
work_keys_str_mv | AT mohammadwaseem organoidsanemergingprecisionmedicinemodelforprostatecancerresearch AT bidarwang organoidsanemergingprecisionmedicinemodelforprostatecancerresearch |